Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC5F3H)

• Drug Name: Isoquinoline sulfonyl derivative 1 Drug Info
• Synonyms: PMID28048944-Compound-13
• Cross-matching ID:
  PubChem CID: 126511157
  TTD Drug ID: DMC5F3H

Molecule-Related Drug Atlas

Drug(s) Targeting Rho-associated protein kinase (ROCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[2]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[3]
Roclatan	DMVQ5X1	Glaucoma/ocular hypertension	9C61	Phase 3	[4]
AR-12286	DM5TC43	Glaucoma/ocular hypertension	9C61	Phase 2	[5]
AMA-76	DMBWNX5	Glaucoma/ocular hypertension	9C61	Phase 2	[6]
Cethrin	DMD3XMW	Spinal cord injury	ND51.2	Phase 1/2	[7]
Y-39983	DMXSEHF	Glaucoma/ocular hypertension	9C61	Phase 1/2	[8]
STM 434	DMDF29A	Ovarian cancer	2C73	Phase 1	[1]
AT13148	DMYIPKJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
Hexahydro azepinone derivative 1	DMC1ZIX	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase (ROCK)	TTMQO60	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
• [2] Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
• [3] Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
• [6] AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
• [7] A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
• [8] Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70.
• [9] Company report (Astex)